medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2020, Number S1

<< Back Next >>

Acta Pediatr Mex 2020; 41 (S1)

SARS-CoV-2 infection. Guidelines on treatment

Cervera-Ubierna A

Language: Spanish
References: 25
Page: 121-126
PDF size: 307.05 Kb.


ABSTRACT

Given the very recent development of infection in humans by SARS coronavirus 2 in the world, there is not yet accepted guidelines for its treatment. In the vast majority of the patients the infection produces mild symptoms and can even be completely asymptomatic. In a small minority of the patients, the infection and result in progressive respiratory distress and multiorgan failure. Isolation of infected individuals to decrease the transmission of the disease in the general population and in the personnel who provide treatment to the patients is essential. Several treatments have been suggested, but up to now none of them have had clearly positive results. Remdesivir, a drug developed for the treatment of Ebola, seems to offer the best possibilities. Prophylactic anticoagulation has been recommended, as a large number of patients suffers from abnormal coagulation. A syndrome similar to Kawasaki disease has been described in children and adolescents either during the period of disease or during convalescence.


REFERENCES

  1. World Health Organization. Director General’s Remarks at the Media Briefing on 2019-nCoV on February2020. Https://www.who.int/dg/speeches/detail/who-directorgeneral- s-remarks-at-the-media-briefing-on-2019-n-covon- 11-February-2020 (revisado el 3 the junio de 2020).

  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical Features of Patients Infected with 2019 Coronavirus in Wuhan China. Lancet 2020; 395 (10223):487.

  3. CDC COVID-19 Response Team: Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19). United States. February 212-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343.

  4. Caí J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A case Series of children with 2019 novel coronavirus infection. Clinical and epidemiological features. Clin Inf Dis. 2020 doi:10.1093/ Cid/ciaa198

  5. Coronavirus Disease 2019 in Childrent-United States. February 12 April 2, 2020. MMWR Morb Mortal Wkly Rep. EPUB: 6 April 2020. Https://www.cdc.gov/MMWR/ volumes/69/24/mm6914e4.htm (revisado el 3 de junio de 2020).

  6. Morand A, Urbina D, Fabre A. COVID 19 and Kawasaki like disease: The known-known and the unknown-unknown. Preprint 2020. 2020050260 doi:10.20944/preprint 20200.0160.v1

  7. Grasselli G, Zangrillo A, Zanella A, Antonella M, Cabrini L, Castelli A, et al. Baseline Characteristics of 1591 Patients Infected with SARS CoV-2 Admitted to ICU’s of the Lombardy Regio, Italy. JAMA 2020 doi: 10.1001/JAMA.2020.5394

  8. CDC COVID-19 ResponseTeam: Coronavirus disease in Children-United States. February 12 - April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020; 691 (14):422.

  9. Bhimaraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis 2020. doi: 10.1093/Cid/cia478

  10. World Health Organization. Home Care for Patients with COVID-19 Presenting with Mild Symptoms and Management of Contacts. Interim Guidance. March 17,2020 https://www.who.int/publications-detail/home-care-forpatients- with-suspected-novel-coronavirus-(ncov)-infection- presenting-with-mild-symptoms-and-managementof- contacts. (Revisado Junio 3, 2020).

  11. 11. Day M. COVID 19 Ibuprofen should not be used to treat symptoms, say doctors and scientists. BMJ 2020; 368. M1086. Doi:10.1136;bmj.m1086 (revisado Marzo 18, 2020)

  12. National Institutes of Health Coronavirus Disease 2019. (COVID 19). Treatment Guidelines. Https://covid19treatmentguidelines. nih.gov/ (revisado junio 3, 2020)

  13. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID 19. Https://www. ema.europa.eu/en/news/ema.gives-advice-on-use-of-nonsteroidal- antiinflamatorios-Covid-19 (Revisado junio 3 2020)

  14. Liu D, Li L, Wu X, Zheng D, Wang J, Yang L et al: Pregnancy and Perinatal outcomes of women with coronavirus disease (COVID19) Pneumonia: A Preliminary Analysis. AJR AM J Roentgenol. 2020 Mar 18;1 doi: 10.2214/AJR. 1012072 (revisado junio 10 2020)

  15. Hantoushzadeh S, Shamshiraz AA, Aleysin A, Seferovich MD, Aski SK, Arian SE, et al: Maternal Death due to COVID-19. Am J Obstet Gynecol.2020 Apr 28; S0002-9378 (20) 30516.0. Doi:10.1016/J AJOG. 2020.04.030

  16. . Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al: Possible vertical transmission of SARS COV2 from an infected mother to newborn. JAMA 2020. Mar 26; 323 (18): 1846. Doi:10/1001/ JAMA.2020.4621 (revisado junio 10, 2020)

  17. Gro BR, Conzelmann C, Muller JA, Stenge S, Steinhart K, Kirchhoff F, et al. Detection of SARS COV2 in human breast milk. Lancer 2020; 395 (10239): 1757

  18. Coronavirus Disease 2019 in children-United States February 12 - April 7, 2020 MMWR Morb Mortal Wkly Rep. https:// www.cdc.gov/MMWR/volumes 69/war/mm6914e4. Htm (revisado junio10, 2020)

  19. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLOS Med. 2020: 3(9): 343

  20. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulation Treatment is Associated with Decreased Mortality in Severe Coronavirus Disease 2019 Patients with Coagulopathy. J Thromb Haemost. 2020; 18(5): 1094

  21. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID 19. Preliminary Report. N Engl J Med. 2020 May 22; nejm Moa 2007764. Doi: 10.1056/nejmoa2007764

  22. USFDA . Coronavirus (COVID19). Update FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. June 15, 2020 https://www.fda.gov/news-events/ press-announcements/coronavirus-COVID-19-update-fdarevokes- emergency-use-authorization-chloroquine-andhydroxychloroquine (revisado junio 10, 2020)

  23. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L. A trial of lopinavir-ritonavir in adults hospitalized with severe COViD- 19. New Engl J Med. 2020; 382(19):1787.

  24. Oxford University News Release. Low cost dexamethasone reduces death by up to one third in hospital patients with severe respiratory complications of COVID19. Https:// www.recoverytrial.net/file/recovery-dexamethasonestatement_ 160620_vzfinal.pdf (revisado junio 15,2020/

  25. Health Alert Network (HAN): multisystem inflammatory syndrome in children (MIS-C) Associated Coronavirus Disease 2019 (COVID-19). Https://emergency.cdc.gov/han/2020/ han00432.asp/.




2020     |     www.medigraphic.com